Home The Word Brain	My Amedeo FAQ Privacy About
	C49 In our changing world, speaking just English isn't enough. Open new doors with skills in another world language. Start with 7 words a day. Next week: +49.

Lung Cancer

Free Subscription 21.04.2025 1 AJR Am J Roentgenol 1 Ann Surg Oncol 2 Ann Thorac Surg 1 Arch Bronconeumol 10 BMC Cancer 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Sci 3 Clin Cancer Res 1 Clin Exp Metastasis 4 Clin Lung Cancer 2 Eur J Cardiothorac Surg 1 Int J Cancer 2 Int J Radiat Oncol Biol Phys 2 J Cancer Res Clin Oncol 2 J Clin Oncol 1 J Thorac Oncol 4 Lung Cancer 1 Lung Cancer (Auckl) 1 Oncol Rep 1 PLoS Med 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. LEE M, Hwang EJ, Lee JH, Nam JG, et al
   Artificial Intelligence for Low-Dose CT Lung Cancer Screening: Comparison of Utilization Scenarios.
   AJR Am J Roentgenol. 2025 Apr 16. doi: 10.2214/AJR.25.32829.
   PubMed         Abstract available
   
   

   
   Ann Surg Oncol

2. ASAMURA H, Yotsukura M, Rami-Porta R, Rusch VW, et al
   Updates on the Version 9 American Joint Committee on Cancer Staging System for Lung Cancer.
   Ann Surg Oncol. 2025 Apr 15. doi: 10.1245/s10434-025-17327.
   PubMed        
   
   

   
   Ann Thorac Surg

3. HOODA Z, Duan Z, Ries S, Antonoff MB, et al
   Association of Medicaid Expansion With Timely Treatment and Access to High-Volume Hospitals in Early-Stage Lung Cancer Patients.
   Ann Thorac Surg. 2025 Apr 11:S0003-4975(25)00321.
   PubMed         Abstract available
   
   
4. CHEN J, Zhao ZR, Deng H, Yang C, et al
   Extended sleeve lobectomy after neoadjuvant immunochemotherapy for centrally located non-small cell lung cancer.
   Ann Thorac Surg. 2025 Apr 9:S0003-4975(25)00298.
   PubMed         Abstract available
   
   

   
   Arch Bronconeumol

5. TRONCHETTI J, Roy P, Laroumagne S, Lovato JB, et al
   Role of Therapeutic Bronchoscopy in Malignant Central Airway Obstruction Due to Small Cell Lung Cancer: Results From the EpiGETIF Registry.
   Arch Bronconeumol. 2025 Mar 20:S0300-2896(25)00086.
   PubMed        
   
   

   
   BMC Cancer

6. WANG FY, Yeh YC, Lin SY, Wang SY, et al
   Real-world application of targeted next-generation sequencing for identifying molecular variants in Asian non-small-cell lung cancer.
   BMC Cancer. 2025;25:715.
   PubMed         Abstract available
   
   
7. LIU C, He Y, Luo J
   The influence of image selection and segmentation on the extraction of lung cancer imaging radiomics features using 3D-Slicer software.
   BMC Cancer. 2025;25:728.
   PubMed         Abstract available
   
   
8. HU D, Hu Y, Lei S, Wu D, et al
   MET tyrosine kinase inhibitors in combination with EGFR tyrosine kinase inhibitors in NSCLC patients with EGFR mutations and acquired MET alterations: a systematic review and meta-analysis.
   BMC Cancer. 2025;25:732.
   PubMed         Abstract available
   
   
9. GAO Y, Hu P, Wu N, Tan F, et al
   A study protocol for the CHinA National CancEr screening (CHANCES) trial: a randomized controlled study to compare the screening strategies for lung cancer and colorectal cancer.
   BMC Cancer. 2025;25:727.
   PubMed         Abstract available
   
   
10. LIAO S, Sun H, Lu H, Wu J, et al
    Neutrophil-to-lymphocyte ratio-based prognostic score can predict outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy plus chemotherapy.
    BMC Cancer. 2025;25:697.
    PubMed         Abstract available
    
    
11. FAN Z, Liu W, Gao Z, Liu Y, et al
    CMSS1: A RNA binding protein with pivotal roles in non-small cell lung cancer progression and prognosis.
    BMC Cancer. 2025;25:688.
    PubMed         Abstract available
    
    
12. XU J, Zhang Z, Han K, Yang Z, et al
    EXOSC5: a novel biomarker for poor prognosis in lung adenocarcinoma.
    BMC Cancer. 2025;25:681.
    PubMed         Abstract available
    
    
13. LI Z, Miao H, Bao W, Zhang L, et al
    Development and validation of a nomogram model of lung metastasis in breast cancer based on machine learning algorithm and cytokines.
    BMC Cancer. 2025;25:692.
    PubMed         Abstract available
    
    
14. KONDO N, Yoshiura T, Kakinohana Y, Yamashita M, et al
    Risk factors for radiation-induced rib fractures following proton beam therapy for stage I non-small cell lung cancer: a retrospective study.
    BMC Cancer. 2025;25:682.
    PubMed         Abstract available
    
    
15. CAO W, Han S, Zhang P, Mi L, et al
    Immune checkpoint inhibitor-related myocarditis in patients with lung cancer.
    BMC Cancer. 2025;25:685.
    PubMed         Abstract available
    
    

    
    Cancer Epidemiol Biomarkers Prev

16. DAVIES MPA, Field JK, Gatto F
    External validation of plasma glycosaminoglycans as biomarkers to improve lung cancer risk stratification.
    Cancer Epidemiol Biomarkers Prev. 2025.
    PubMed         Abstract available
    
    

    
    Cancer Sci

17. OCHI T, Fujiki R, Fukuyo M, Rahmutulla B, et al
    Association of Intratumoral Bacterial Abundance With Lung Cancer Prognosis in Chiba University Hospital Cohort.
    Cancer Sci. 2025 Apr 11. doi: 10.1111/cas.70080.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

18. PECCI F, Thummalapalli R, Alden SL, Ricciuti B, et al
    Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung Cancer.
    Clin Cancer Res. 2025 Apr 18:OF1-OF13. doi: 10.1158/1078-0432.CCR-24-2990.
    PubMed         Abstract available
    
    
19. JENG MY, Schoenfeld AJ
    Can Longitudinal Biomarkers Guide Treatment Decisions? Time Will Tell.
    Clin Cancer Res. 2025;31:1381-1382.
    PubMed         Abstract available
    
    
20. MAZZASCHI G, Marrocchio C, Moron Dalla Tor L, Leo L, et al
    Longitudinal Blood Immune-Inflammatory and Radiomic Profiling to Decode Different Patterns of Acquired Resistance to Immunotherapy in Patients with NSCLC.
    Clin Cancer Res. 2025;31:1533-1545.
    PubMed         Abstract available
    
    

    
    Clin Exp Metastasis

21. YANG L, Li J
    Interplay of GPC3, Hsa-miR-135b-3p, and FTLP3 in lung cancer metastasis.
    Clin Exp Metastasis. 2025;42:26.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

22. SHARGALL Y, Vella ET, Del Giudice ME, Dennie C, et al
    Systematic Review for the Follow-up of Curatively Treated Patients With Lung Cancer.
    Clin Lung Cancer. 2025 Mar 19:S1525-7304(25)00049.
    PubMed         Abstract available
    
    
23. ELKEFI S, Phillips E, Groner LK, Matthews AK, et al
    Predictors of Up-To-Date Lung Cancer Screening Among Eligible People in the United States: A Nationally Representative Dataset.
    Clin Lung Cancer. 2025 Mar 17:S1525-7304(25)00051.
    PubMed         Abstract available
    
    
24. CHANG LC, Hu HW, Hsieh MS, Wu SG, et al
    Brief Report: The Effectiveness of Osimertinib in Advanced Nonsmall Cell Lung Cancer Harboring Various EGFR Exon 19 Mutation Variants.
    Clin Lung Cancer. 2025 Mar 21:S1525-7304(25)00054.
    PubMed        
    
    
25. CASTANEDA-GONZALEZ JP, Parra-Medina R, Riess JW, Gandara DR, et al
    Genetic Ancestry and Lung Cancer in Latin American Patients: A Crucial Step for Understanding a Diverse Population.
    Clin Lung Cancer. 2025 Mar 13:S1525-7304(25)00050.
    PubMed         Abstract available
    
    

    
    Eur J Cardiothorac Surg

26. SHENG Z, Ji S, Chen Y, Mi Z, et al
    Machine learning algorithms integrating positron emission tomography/computed tomography features to predict pathological complete response after neoadjuvant chemoimmunotherapy in lung cancer.
    Eur J Cardiothorac Surg. 2025 Apr 12:ezaf132. doi: 10.1093.
    PubMed         Abstract available
    
    
27. TSUBOKAWA N, Mimae T, Miyata Y, Kanno C, et al
    Comparative oncological features of centrally- and peripherally-located small sized radiologically solid-dominant non-small cell lung cancer.
    Eur J Cardiothorac Surg. 2025 Apr 12:ezaf072. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Int J Cancer

28. NOFAL S, J Ostrin E, Zhang J, Wu J, et al
    Risk of second primary lung cancer among cancer survivors stratified by the site of first primary cancer and the lung cancer screening eligibility status.
    Int J Cancer. 2025 Apr 18. doi: 10.1002/ijc.35452.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

29. NAGLER F, Vorbach S, Mohamed AA, Thaqi S, et al
    Pulmonary Stereotactic Body Radiotherapy of Oligometastatic Head-and-Neck Squamous Cell Carcinoma - A multicenter retrospective study.
    Int J Radiat Oncol Biol Phys. 2025 Jan 4:S0360-3016(24)03771.
    PubMed         Abstract available
    
    
30. KEANE F, Daly M, Louie A, Harris J, et al
    Resistance is Futile: Stereotactic Body Radiation Therapy for Oligoprogressive Non-small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2025;122:1-4.
    PubMed        
    
    

    
    J Cancer Res Clin Oncol

31. SHIGETA N, Murakami S, Yamamoto K, Yokose T, et al
    Comparison of programmed death ligand-1 expression in preoperative transbronchial lung biopsy and resected specimens in non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2025;151:139.
    PubMed         Abstract available
    
    
32. WU S, Hu C, Hu P, He W, et al
    RAF1 promotes anlotinib resistance in non-small cell lung cancer by inhibiting apoptosis.
    J Cancer Res Clin Oncol. 2025;151:138.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

33. MIURA S, Tanaka H, Misumi T, Yoshioka H, et al
    Pragmatic Randomized Study of Afatinib Versus Chemotherapy for Patients With Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations: ACHILLES/TORG1834.
    J Clin Oncol. 2025 Apr 16:JCO2402007. doi: 10.1200/JCO-24-02007.
    PubMed         Abstract available
    
    
34. SCHYTTE T, Knap MM, Kristiansen C, Appelt AL, et al
    Toxicity Within 6 Months of Heterogeneous Fluorodeoxyglucose-Guided Radiotherapy Dose Escalation for Locally Advanced Non-Small Cell Lung Cancer in the Scandinavian Randomized Phase III NARLAL2 Trial.
    J Clin Oncol. 2025 Apr 18:JCO2401386. doi: 10.1200/JCO-24-01386.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

35. HAMADA A, Soh J, Hata A, Nakamatsu K, et al
    Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 Non-Small Cell Lung Cancer: Primary Results from SQUAT trial (WJOG 12119L).
    J Thorac Oncol. 2025 Apr 9:S1556-0864(25)00656.
    PubMed         Abstract available
    
    

    
    Lung Cancer

36. WU Q, Li Q, Qin Y
    A cost-effectiveness analysis of amivantamab plus lazertinib versus osimertinib in the treatment of US and Chinese patients with EGFR-mutated advanced non-small cell lung cancer.
    Lung Cancer. 2025;203:108533.
    PubMed         Abstract available
    
    
37. ROSENLUND L, Guldbrandsen K, Ahlborn LB, Bloch M, et al
    ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach.
    Lung Cancer. 2025;203:108528.
    PubMed         Abstract available
    
    
38. PAN Y, Gu Q
    Efficacy and safety of targeted therapy combined with anti-angiogenesis treatment in brain metastases of non-small cell lung cancer: a systematic review and meta-analysis.
    Lung Cancer. 2025;203:108532.
    PubMed         Abstract available
    
    
39. VAES RDW, Cortiula F, Lyu S, Hiltermann TJN, et al
    Chemoradiotherapy efficacy in patients with stage III non-small cell lung cancer (NSCLC): A prognostic clinical and biomarker-based model.
    Lung Cancer. 2025;203:108541.
    PubMed         Abstract available
    
    

    
    Lung Cancer (Auckl)

40. CHEN CY, Ko HW, Hu PW, Chang CY, et al
    Impact of Subsequent Treatment on Clinical Outcomes in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Transformed to Small-Cell Lung Cancer.
    Lung Cancer (Auckl). 2025;16:25-37.
    PubMed         Abstract available
    
    

    
    Oncol Rep

41. YUAN Q, Li X, Chen X, Xiao J, et al
    7?Difluoromethoxyl?5,4'?di?n?octylygenistein targets the STAT3 pathway by upregulating microRNA?152?3p expression to inhibit self?renewal and tumor growth in non?small cell lung carcinoma.
    Oncol Rep. 2025;53:66.
    PubMed         Abstract available
    
    

    
    PLoS Med

42. SCHUURBIERS MMF, Smith CG, Hartemink KJ, Rintoul RC, et al
    Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: A retrospective validation study.
    PLoS Med. 2025;22:e1004574.
    PubMed         Abstract available
    
    

    
    PLoS One

43. PRAKAIKIETIKUL P, Wannasopha Y, Euathrongchit J, Tantraworasin A, et al
    CT features and histogram analysis of non-contrast images for differentiating malignant and benign mediastinal lymph nodes in Non-Small Cell Lung Cancer (NSCLC).
    PLoS One. 2025;20:e0321921.
    PubMed         Abstract available
    
    
44. GAO C, Liu M, Sun Y, Zhao Z, et al
    Association between advanced lung cancer inflammation index and gallstone prevalence among U.S. adults: A population-based study.
    PLoS One. 2025;20:e0321733.
    PubMed         Abstract available
    
    
45. KUO P, Elboudwarej E, Zavodovskaya M, Lin KW, et al
    Trop-2 expression in non-small cell lung cancer.
    PLoS One. 2025;20:e0321555.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.